VANCOUVER, British Columbia–(BUSINESS WIRE)–SaNOtize Research & Development Corp., (“SaNOtize”), a Canadian anti-infective-focused therapeutics company, today announced an oversubscribed $24 million Series B funding to advance its nitric oxide-based therapeutics pipeline. The lead treatment in the pipeline is the company’s nitric oxide nasal spray (NONS™), shown in clinical studies to treat and prevent COVID-19 infection, including a recent Phase 3 study published in The Lancet Regional Health Southeast Asia. The new funding round was co-led by Horizons Ventures and OurCrowd, with participation from ABC International, and enables SaNOtize to expand its research program, including its ongoing global Phase 3 NONS prevention clinical study with plans to recruit up to 3,000 participants in Canada and Sri Lanka.

Read more here.